NCT04026984View on ClinicalTrials.gov

Evaluate Safety and Efficacy of Rifamycin SV MMX in the Treatment of Traveler's Diarrhea in Children Age 6 to 11 Years

PHASE2Not yet recruitingINTERVENTIONAL

Enrollment

142

Participants

Timeline

Start Date

June 30, 2024

Primary Completion Date

June 30, 2025

Study Completion Date

December 31, 2025

Conditions

Traveler's Diarrhea

Interventions

DRUG

Rifamycin SV-MMX

2 Rifamycin SV-MMX® 50 mg tablets b.i.d. plus ORT

DRUG

Placebo

Matching Placebo tablets

All Listed Sponsors

lead

RedHill Biopharma Limited

INDUSTRY